MERGER OF GRUG GIANTS: THE SPECULATION; Value of Zeneca Soars, in Part Because It's Viewed as a Targ...
MERGER OF GRUG GIANTS: THE SPECULATION; Value of Zeneca Soars, in Part Because It's Viewed as a Target
About this item
Full title
Author / Creator
Publisher
New York, N.Y: New York Times Company
Journal title
Language
English
Formats
Publication information
Publisher
New York, N.Y: New York Times Company
Subjects
More information
Scope and Contents
Contents
Traders said the merger, along with higher earnings reported by the British drug maker, raised the chance that Roche Holding A.G. or another pharmaceuticals company might offer to buy Zeneca, Britain's third-largest drug maker. About half of Zeneca's sales come from cardiovascular drugs and a strong franchise in cancer treatments. Zeneca's results...
Alternative Titles
Full title
MERGER OF GRUG GIANTS: THE SPECULATION; Value of Zeneca Soars, in Part Because It's Viewed as a Target
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_newspapers_430532139
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_newspapers_430532139
Other Identifiers
ISSN
0362-4331
